| Symbol | PRAX |
|---|---|
| Name | PRAXIS PRECISION MEDICINES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 99 HIGH STREET,30TH FLOOR, BOSTON, Massachusetts, 02110, United States |
| Telephone | +1 617 - 300-8460 |
| Fax | — |
| — | |
| Website | https://www.praxismedicines.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001689548 |
| Description | Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal imbalance. The firms pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinsons Disease; PRAX-562, and PRAX-222, among others. Additional info from NASDAQ: |
(99% Neutral) PRAXIS PRECISION MEDICINES, INC. (PRAX) Announces Business Combination
Read morePraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read more(99% Neutral) PRAXIS PRECISION MEDICINES, INC. (PRAX) Announces Clinical Development Update
Read morePraxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Read moreDirector DeSimone Jill 🟡 adjusted position in 11.6K shares (2 derivative) of Praxis Precision Medicines, Inc. (PRAX) at $315.70 ($5.3M) Transaction Date: Jun 24, 2026 | Filing ID: 000003
Read more📋 DeSimone Jill (Director) plans to sell 12K shares of Praxis Precision Medicines, Inc. (at $311.32 each, total $3.6M) Filed: Jun 24, 2026 | ID: 004864
Read more(99% Neutral) PRAXIS PRECISION MEDICINES, INC. (PRAX) Announces Clinical Development Update
Read moreDirector Arbuckle Stuart A 🟢 acquired 2.0K shares (1 derivative) of Praxis Precision Medicines, Inc. (PRAX) at $240.66 Transaction Date: Jun 10, 2026 | Filing ID: 000064
Read moreDirector Chodakewitz Jeffrey 🟢 acquired 2.0K shares (1 derivative) of Praxis Precision Medicines, Inc. (PRAX) at $240.66 Transaction Date: Jun 10, 2026 | Filing ID: 000063
Read moreDirector YOUNG WILLIAM D 🟢 acquired 2.0K shares (1 derivative) of Praxis Precision Medicines, Inc. (PRAX) at $240.66 Transaction Date: Jun 10, 2026 | Filing ID: 000062
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07505004 | Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of V… | Phase3 | Focal Epilepsy | Recruiting | 2026-01-29 | 2027-05-01 | ClinicalTrials.gov |
| NCT07287163 | Clinical Trial of Vormatrigine in Adult Patients With Epilepsy | Phase3 | Epilepsy, Tonic-Clonic | Enrolling_By_Invitation | 2025-10-27 | 2028-12-31 | ClinicalTrials.gov |
| NCT07019922 | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Sa… | Phase3 | Epileptic Encephalopathy | Recruiting | 2025-08-13 | 2028-12-01 | ClinicalTrials.gov |
| NCT07010471 | A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerabi… | Phase3 | Developmental and Epileptic Encephalopathy 1 | Recruiting | 2025-07-09 | 2027-11-01 | ClinicalTrials.gov |
| NCT06840925 | A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628 | Phase1 | Healthy | Not_Yet_Recruiting | 2025-03-24 | 2025-06-30 | ClinicalTrials.gov |
| NCT06908356 | An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults W… | Phase2 | Focal Onset Seizure | Recruiting | 2025-01-10 | 2025-07-01 | ClinicalTrials.gov |
| NCT06999902 | Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Eva… | Phase2 | Focal Seizure | Recruiting | 2024-12-11 | 2025-12-08 | ClinicalTrials.gov |
| NCT06087276 | Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy o… | Phase3 | Essential Tremor | Enrolling_By_Invitation | 2023-11-02 | 2026-12-01 | ClinicalTrials.gov |
| NCT05818553 | A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encep… | Phase2 | SCN2A Encephalopathy | Active_Not_Recruiting | 2023-08-02 | 2027-03-01 | ClinicalTrials.gov |
| NCT05737784 | A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A D… | Phase1 | SCN2A-DEE | Recruiting | 2023-04-13 | 2027-09-01 | ClinicalTrials.gov |
| NCT05407727 | A Prospective, Remote Observational Study in Pediatric Participants With Early-… | — | SCN2A-DEE | Completed | 2022-04-15 | 2023-03-31 | ClinicalTrials.gov |
| NCT05387642 | A Clinical Trial of PRAX-114 in Participants With Essential Tremor | Phase2 | Essential Tremor | Withdrawn | 2022-04-05 | 2022-06-30 | ClinicalTrials.gov |
| NCT05260541 | A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder | Phase2 | Post-traumatic Stress Disorder | Terminated | 2022-01-25 | 2022-09-23 | ClinicalTrials.gov |
| NCT05021991 | A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor | Phase2 | Essential Tremor | Completed | 2021-10-14 | 2024-02-29 | ClinicalTrials.gov |
| NCT04969510 | A Clinical Trial of Adjunctive and Monotherapy PRAX-114 in Participants With Ma… | Phase2 | Major Depressive Disorder | Completed | 2021-06-24 | 2022-08-02 | ClinicalTrials.gov |
| NCT04832425 | A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder | Phase2 | Major Depressive Disorder | Completed | 2021-03-30 | 2022-05-05 | ClinicalTrials.gov |
| NCT05021978 | A Clinical Trial of PRAX-944 in Participants With Essential Tremor | Phase2 | Essential Tremor | Completed | 2020-03-03 | 2022-03-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| sham procedure | Procedure | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| sham procedure | Procedure | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| sham procedure | Procedure | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| sham procedure | Procedure | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| sham procedure | Procedure | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| sham procedure | Procedure | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| Placebo | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.5mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.0mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| Placebo | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.5mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.0mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| Placebo | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.5mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.0mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| Placebo | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.5mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.0mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| Placebo | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.5mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.0mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| Placebo | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.5mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.0mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| Flexibly dosed 20 mg to 100 mg PRAX-944 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05021991 |
| Placebo | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05021991 |
| 60 mg PRAX-944 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05021991 |
| 100 mg PRAX-944 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05021991 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04832425 |
| PRAX-114 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04832425 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04969510 |
| 60 mg PRAX-114 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04969510 |
| 40 mg PRAX-114 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04969510 |
| 20 mg PRAX-114 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04969510 |
| 10 mg PRAX-114 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT04969510 |
| 10 mg PRAX-114 or 20 mg PRAX-114 | Other | Phase PHASE2 | Essential Tremor | WITHDRAWN | NCT05387642 |
| 10 mg PRAX-114, 20 mg PRAX-114, and Placebo | Other | Phase PHASE2 | Essential Tremor | WITHDRAWN | NCT05387642 |
| 40 mg PRAX-114 | Other | Phase PHASE2 | Post-traumatic Stress Disorder | TERMINATED | NCT05260541 |
| Placebo | Other | Phase PHASE2 | Post-traumatic Stress Disorder | TERMINATED | NCT05260541 |
| 60 mg PRAX-114 or 40 mg PRAX-114 | Other | Phase PHASE2 | Post-traumatic Stress Disorder | TERMINATED | NCT05260541 |
| Part B: 120 mg PRAX-944 and Placebo | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05021978 |
| Part B: 120 mg PRAX-944 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05021978 |
| Part A: 20 and 40 mg PRAX-944 | Other | Phase PHASE2 | Essential Tremor | COMPLETED | NCT05021978 |
| PRAX-628 | Other | Phase PHASE1 | Healthy | NOT_YET_RECRUITING | NCT06840925 |
| 30mg PRAX-628 | Other | Phase PHASE2 | Focal Onset Seizure | RECRUITING | NCT06908356 |
| Placebo | Other | Phase PHASE2 | Focal Seizure | RECRUITING | NCT06999902 |
| 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks | Other | Phase PHASE2 | Focal Seizure | RECRUITING | NCT06999902 |
| Placebo | Other | Phase PHASE1 | SCN2A-DEE | RECRUITING | NCT05737784 |
| PRAX-222 - Fixed Doses | Other | Phase PHASE1 | SCN2A-DEE | RECRUITING | NCT05737784 |
| PRAX-222 - Optional Ascending Doses | Other | Phase PHASE1 | SCN2A-DEE | RECRUITING | NCT05737784 |
| PRAX-222 - Initial Ascending Doses | Other | Phase PHASE1 | SCN2A-DEE | RECRUITING | NCT05737784 |
| PRAX-222 - Initial Dose | Other | Phase PHASE1 | SCN2A-DEE | RECRUITING | NCT05737784 |
| Placebo | Other | Phase PHASE3 | Essential Tremor | ENROLLING_BY_INVITATION | NCT06087276 |
| 60 mg ulixacaltamide | Other | Phase PHASE3 | Essential Tremor | ENROLLING_BY_INVITATION | NCT06087276 |
| 0.5mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| sham procedure | Procedure | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| 1mg elsunersen | Other | Phase PHASE3 | Epileptic Encephalopathy | RECRUITING | NCT07019922 |
| vormatrogine | Other | Phase PHASE3 | Epilepsy, Tonic-Clonic | ENROLLING_BY_INVITATION | NCT07287163 |
| Placebo | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.5mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| 1.0mg/kg/day PRAX-562 | Other | Phase PHASE3 | Developmental and Epileptic Encephalopathy 1 | RECRUITING | NCT07010471 |
| PRAX-562 | Other | Phase PHASE2 | SCN2A Encephalopathy | ACTIVE_NOT_RECRUITING | NCT05818553 |
| Placebo | Other | Phase PHASE3 | Focal Epilepsy | RECRUITING | NCT07505004 |
| 20 mg/day vormatrogine for 12 weeks | Other | Phase PHASE3 | Focal Epilepsy | RECRUITING | NCT07505004 |
| 30 mg/day vormatrogine for 12 weeks | Other | Phase PHASE3 | Focal Epilepsy | RECRUITING | NCT07505004 |
| 40 mg/day vormatrogine for 12 weeks | Other | Phase PHASE3 | Focal Epilepsy | RECRUITING | NCT07505004 |